JHOP Articles

Skip to main content

From the Literature, Transplant, Adverse Events

Sitagliptin, a DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant

FDA Updates, Multiple Myeloma

Xpovio Approved for Patients with Relapsed or Refractory Multiple Myeloma

FDA Updates, Lung Cancer

Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations

FDA Updates, Lymphoma

Xalkori Approved for Anaplastic Large-Cell Lymphoma and ALK Mutation in Young Patients

FDA Updates, Breast Cancer

FDA Approves Margenza for the Treatment of Metastatic HER2-Positive Breast Cancer

FDA Updates, Prostate Cancer

Orgovyx First FDA-Approved Oral Hormone Therapy for Advanced Prostate Cancer

Meeting Highlights

ASH Highlights, Leukemia

Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia

Meeting Highlights

ASH Highlights, Myelofibrosis

Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis

Meeting Highlights

ASH Highlights, CAR T-Cell Therapy, Lymphoma

ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma

Meeting Highlights

ASH Highlights, Clinical Trials, Lymphoma

Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma

Page 93 of 196
Results 921 - 930 of 1954